Boston Scientific (NYSE:BSX) PT Raised to $85.00 at Mizuho

Boston Scientific (NYSE:BSX) had its price target increased by Mizuho from $80.00 to $85.00 in a report released on Thursday, Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other analysts have also commented on the company. Raymond James boosted their price objective on Boston Scientific from $67.00 to $73.00 and gave the stock a strong-buy rating in a report on Thursday, February 1st. StockNews.com lowered Boston Scientific from a buy rating to a hold rating in a report on Saturday, March 16th. JPMorgan Chase & Co. boosted their price objective on Boston Scientific from $60.00 to $72.00 and gave the stock an overweight rating in a report on Thursday, February 1st. Royal Bank of Canada boosted their price objective on Boston Scientific from $70.00 to $78.00 and gave the stock an outperform rating in a report on Monday, April 15th. Finally, Citigroup boosted their price objective on Boston Scientific from $71.00 to $79.00 and gave the stock a buy rating in a report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $74.27.

Boston Scientific Trading Down 0.0 %

Shares of NYSE:BSX traded down $0.02 during midday trading on Thursday, reaching $73.24. The company’s stock had a trading volume of 351,068 shares, compared to its average volume of 6,485,329. The firm has a market capitalization of $107.45 billion, a price-to-earnings ratio of 61.60, a PEG ratio of 2.48 and a beta of 0.78. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The firm has a 50 day moving average price of $67.68 and a two-hundred day moving average price of $60.37. Boston Scientific has a fifty-two week low of $48.35 and a fifty-two week high of $74.39.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same period in the previous year, the company posted $0.45 EPS. As a group, analysts forecast that Boston Scientific will post 2.32 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, EVP John Bradley Sorenson sold 16,351 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total value of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares of the company’s stock, valued at $3,509,213.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,979 shares of company stock valued at $3,418,529. 0.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BSX. Bruce G. Allen Investments LLC bought a new position in Boston Scientific in the fourth quarter valued at $28,000. Northwest Investment Counselors LLC bought a new position in shares of Boston Scientific during the first quarter valued at about $31,000. Sachetta LLC bought a new position in shares of Boston Scientific during the fourth quarter valued at about $32,000. Frazier Financial Advisors LLC bought a new position in shares of Boston Scientific during the fourth quarter valued at about $32,000. Finally, Jones Financial Companies Lllp grew its stake in shares of Boston Scientific by 53.0% during the fourth quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 193 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.